CD44 and breast carcinoma: Further, we downloaded RNA‐Seq data from breast cancer patients from TCGA‐breast cancer database and found that the expression level of SPRY4‐IT1 was significantly higher in patients with CD44+/CD24‐ breast cancer (n = 237) than those without CD44+/CD24− (n = 872) (Figure 1E).